Osiris Therapeutics Inc. rose the most in eight months after European regulators transferred the orphan drug title for a stem cell therapy to the company, making it easier to seek a buyer or partner for the treatment.
Regeneron Pharmaceuticals Inc. declined as much as 13 percent in extended trading after U.S. regulators delayed a decision on whether to approve the company’s treatment for a common cause of blindness.
Sarepta Therapeutics Inc. tripled in trading after its drug for Duchenne muscular dystrophy helped patients walk farther in a study and restored a key protein lacking in some of those with the disease.
Arena Pharmaceuticals Inc.’s weight- loss pill, the first cleared in the U.S. in 13 years, and an expected rival are potential breakthroughs in the treatment of obesity that may spur major drugmakers into the market.
Eisai Co. surged the most in two years in Tokyo trading after its partner won Food and Drug Administration approval for a weight-loss pill, making it the first obesity medication cleared for the U.S. in 13 years.
Exelixis Inc., a biotechnology company with no approved products, plunged the most in 11 years after failing to agree with U.S. regulators on special rules for a study of its experimental prostate cancer drug.
Micromet Inc. , a 17-year-old biotechnology company with no medicines on the market, is attracting attention from product-hungry drugmakers. The lure: a technology for fighting cancer without using toxic chemicals.
Osiris Therapeutics Inc. rose after the company said it won the world’s first approval for a stem- cell drug, gaining clearance in Canada to sell Prochymal for a disease that can attack patients who received bone-marrow transplants.